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SUZ12 is a recently identiﬁed Polycomb group (PcG)
protein, which together with EZH2 and EED forms differ-
ent Polycomb repressive complexes (PRC2/3). These com-
plexes contain histone H3 lysine (K) 27/9 and histone H1
K26 methyltransferase activity speciﬁed by the EZH2 SET
domain. Here we show that mice lacking Suz12, like Ezh2
and Eed mutant mice, are not viable and die during early
postimplantation stages displaying severe developmental
and proliferative defects. Consistent with this, we demon-
strate that SUZ12 is required for proliferation of cells in
tissue culture. Furthermore, we demonstrate that SUZ12 is
essential for the activity and stability of the PRC2/3 com-
plexes in mouse embryos, in tissue culture cells and in
vitro. Strikingly, Suz12-deﬁcient embryos show a speciﬁc
loss of di- and trimethylated H3K27, demonstrating that
Suz12 is indeed essential for EZH2 activity in vivo. In
conclusion, our data demonstrate an essential role of
SUZ12 in regulating the activity of the PRC2/3 complexes,
which are required for regulating proliferation and em-
bryogenesis.
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Introduction
Polycomb group proteins (PcG) and Trithorax proteins reg-
ulate the correct expression of HOX genes by maintaining
their repressive or active transcriptional state, respectively.
Both classes of proteins are essential for Drosophila develop-
ment and their mutations lead to homeotic transformation
and ﬂy lethality (Brock and van Lohuizen, 2001; Jacobs and
van Lohuizen, 2002). PcG proteins are conserved throughout
evolution, forming multiprotein complexes that regulate tran-
scription through the induction of chromatin changes
(Jenuwein and Allis, 2001).
In mammals, the best-characterized PcG complexes are
the Polycomb repressive complexes (PRC), PRC1 and PRC2.
PRC1 is a large complex consisting of more than 10 subunits,
including the oncoprotein BMI1 as well as other PcG proteins,
such as HPC, HPH and SCML (Jacobs and van Lohuizen,
2002). The PRC2 complex is a smaller complex containing
at least four different subunits, including the three PcG
proteins EZH2, EED and SUZ12 and the histone-binding
proteins RbAp48/46 (reviewed in Cao and Zhang, 2004;
Pasini et al, 2004). Recent ﬁndings have also reported the
existence of an alternative larger form of the PRC2 complex
named PRC3 containing EZH2, SUZ12, RbAp48/46 and two
isoforms of EED (Kuzmichev et al, 2004). The EZH2-contain-
ing complexes (PRC2/3) have intrinsic histone methyltrans-
ferase (HMT) activities, by methylating lysine (K) residues 9
and 27 of histone H3 and K26 of histone H1. These modiﬁca-
tions are dependent on the integrity of the EZH2 SET domain,
and are believed to result in transcriptional repression of
target genes (Cao and Zhang, 2004; Kuzmichev et al, 2004).
Recent results have shown that the PcG genes of the
mammalian PRC2/3 complexes, EZH2, EED and SUZ12, are
downstream targets of the pRB/E2F pathway (Weinmann
et al, 2001; Bracken et al, 2003). Moreover, we and others
have shown that both EZH2 and EED are essential for
proliferation of primary and tumor cells (Varambally et al,
2002; Bracken et al, 2003). Consistent with the fact that
deregulation of the pRB pathway is a hallmark of human
cancer, recent data have demonstrated that EZH2 is over-
expressed in a wide spectrum of human tumors, and its
overexpression can be due to ampliﬁcation of the EZH2
locus. Furthermore, EZH2 is a marker of the metastatic
state of prostate and breast tumors and may have a causal
role in development of cancer (Varambally et al, 2002;
Bracken et al, 2003; Kleer et al, 2003). Indeed, ectopic
expression of EZH2 can promote growth advantage in
mouse embryo ﬁbroblasts (MEFs) and can induce cellular
transformation and invasive capacity to immortalized human
breast epithelial cells (Bracken et al, 2003; Kleer et al, 2003).
The SUZ12 protein is the most recently identiﬁed protein of
the EZH2-containing complexes. It contains two stretches of
conserved amino acids (aa) containing a zinc-ﬁnger binding
motif and a VEFS box, which is required for the interaction
between SUZ12 and EZH2 (Yamamoto et al, 2004). To date,
the physiological and functional role of SUZ12 in mammals
has not been addressed, although the SUZ12 locus is part of
a frequent translocation identiﬁed in endometrial stromal
sarcomas (ESSs) (Koontz et al, 2001). The predicted fusion
protein contains 88% of the C-terminal part of SUZ12, fused
at its N-terminus to an uncharacterized zinc-ﬁnger-contain-
ing protein. These data suggest that overexpression of SUZ12
and/or the generation of a fusion protein with additional
features to SUZ12 has a causal role in the genesis of ESSs.
Studies in Drosophila showed that consistent with being
a PcG protein, su(z)12 mutations lead to strong homeotic
transformation and ﬂy lethality (Birve et al, 2001). Su(z)12 is
conserved from plants to humans (Birve et al, 2001).
Interestingly, even though Caenorhabditis elegans has EZH2
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and EED homologs in a complex that retains H3 K27 HMT
activity, this complex does not contain a SUZ12 homolog and
a SUZ12 C. elegans homolog has not been identiﬁed (Cao
and Zhang, 2004). This ﬁnding raises the question whether
SUZ12 is required for PRC2/3 HMT activities, and if the
biological function of SUZ12 is exerted through the binding
to EZH2 and EED.
In this work we have addressed the biological and func-
tional role of SUZ12 in mammals. We show that mice lacking
Suz12 are not viable and die during embryogenesis at early
postimplantation stages. We demonstrate that Suz12 is re-
quired for cellular proliferation, and that it is essential for the
HMT activity of the PRC2/3 complexes both in vivo and in
tissue culture. Furthermore, we show that SUZ12 is essential
for the integrity of the PRC2/3 complexes and for the stability
of EZH2. Taken together with the fact that both Ezh2 and Eed,
as the Suz12 knockout mice, die during the postimplantation
period of embryogenesis (Faust et al, 1995; O’Carroll et al,
2001), our data demonstrate that SUZ12 is an essential
regulator of the activity of the EZH2-containing complexes.
Results
Analysis of Suz12 genetrap embryonic stem cells
To characterize the role of Suz12 in mouse development, we
generated a mouse model lacking Suz12. An embryonic stem
(ES) cell line containing a genetrap vector inserted in the
Suz12 locus on mouse chromosome 11 was identiﬁed in the
BayGenomics database (http://www.baygenomics.ucsf.edu).
In this cell line, the genetrap cassette is inserted in the intron
between exons 7 and 8 (Figure 1A). This insertion is pre-
dicted to lead to a C-terminal truncation of Suz12, resulting in
the production of 276 N-terminal amino acids of Suz12 fused
to 1323 aa of the b-galactosidase-neomycin (b-GEO) protein
with a molecular weight of 179 kDa (Figure 1B). The trun-
cated form of Suz12 does not contain the two conserved
regions of the wild-type (WT) protein, including the domain
required for binding to EZH2 (Yamamoto et al, 2004). This
suggests that the truncated form of Suz12 would be a
functionally inactive mutant. This is supported by the de-
monstration that production of a similar mutant form of
Drosophila su(z)12 leads to strong homeotic transformations
and ﬂy lethality (Birve et al, 2001).
We analyzed the Suz12 genetrap ES cells to conﬁrm the
correct positioning and functionality of the insertion cassette.
We designed a probe that speciﬁcally recognizes the genetrap
cassette, and performed ﬂuorescence in situ hybridization
(FISH) analysis on metaphase spreads of Suz12 genetrap
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Figure 1 Suz12 is essential for mouse viability. (A) Close-up be-
tween exons 7 and 8 of the Suz12 locus is presented for both the WT
(top panel) and the genetrap (KO) clones (bottom part). The
strategies for genotyping the mice are presented. The probe is
indicated (black horizontal bar) as well as the restriction sites
(ACC1) used for Southern blot analysis. The PCR primers used
are also indicated. The WTallele is detected by ampliﬁcation of the
entire intron 7. The presence of the KO allele was detected by PCR
as part of the LacZ gene contained in the genetrap cassette. All
fragments and ampliﬁed product sizes are indicated in kilobases.
(B) Schematical representation of the WT Suz12 protein with the
two conserved regions indicated, and the truncation products
obtained in the KO mice. (C) FISH analysis of metaphase spreads
of WTand Suz12 genetrap ES cells showing normal karyotype of the
ES cells and a single insertion of the genetrap cassette in Suz12
targeted cells. (D) Southern blot analysis of WTand Suz12 genetrap
ES cells showing the presence of the KO cassette in the Suz12 locus.
(E) WB analysis showing the expression of the Suz12 WT protein in
ES cells and the expression of the Suz12-b-GEO fusion only in the
targeted ES cells. (F) Southern blot analysis showing the absence of
Suz12 / mice from Suz12þ / intercrosses. (G) Summary table
of the genotype of mice born from Suz12þ / intercrosses demon-
strating that Suz12 KO mice are not born.
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ES cells, which showed that the ES cells present a normal
number of chromosomes and one single insertion of the
genetrap cassette (Figure 1C). To conﬁrm that the insertion
cassette was placed in the correct locus, we performed
Southern blotting and polymerase chain reaction (PCR) to
screen for the presence of both the WTand the targeted (KO)
Suz12 alleles (Figure 1A). Southern blot analysis on WT and
Suz12 genetrap ES cells showed that only the WT allele was
present in WT ES cells, whereas the Suz12þ / ES cells
contain both the WTand KO alleles (Figure 1D). As a further
control, we showed that while WT Suz12 is expressed in all
the analyzed ES cells, a genetrap fusion protein of the
predicted molecular weight was only detectable in the
Suz12 heterozygous ES cells (Figure 1E). Thus, we conclude
that the ES Suz12 genetrap cells contain one insertion cas-
sette, leading to the C-terminal truncation of the SUZ12
protein.
Generation of Suz12 KO mice
Several highly chimeric mice (490%) were generated upon
injection of the Suz12 genetrap ES cells. Three chimeric
males were crossed with WT C57BL/6 females and we
obtained germline transmission of the Suz12 KO allele. We
did not observe any phenotypic differences between WT and
Suz12 heterozygous mice, when analyzing size, morphology
and fertility (data not shown).
To generate Suz12 KO mice, we crossed Suz12þ / mice
and genotyped 147 pups either by Southern blotting or PCR
analysis (Figure 1F). We did not identify any Suz12 KO mice
among the 147 pups analyzed, suggesting that Suz12 deple-
tion results in embryonic lethality. This is supported by the
correct Mendelian ratio between Suz12þ / and Suz12þ /þ
mice (Figure 1G).
Developmental defects in Suz12 KO embryos
To understand when loss of Suz12 induces embryonic leth-
ality, we analyzed embryos generated from Suz12 heterozy-
gous crosses, at different stages of development. While we
did not detect the presence of Suz12 KO embryos at later
stages, at 10.5 days post coitus (dpc) we found embryonic
tissues in smaller deciduae that were nearly completely
reabsorbed. PCR analysis on genomic DNA demonstrated
that Suz12/ embryos are nearly completely reabsorbed,
suggesting that embryonic lethality occurs at earlier embryo-
nic stages (Figure 2A).
At 8.5 dpc, we found normal as well as much smaller
embryos with morphology similar to that of a 7.5 dpc em-
bryo. PCR analysis of these embryos showed that they were
Suz12 KO, suggesting that the effects of Suz12 loss arise at
around 7.5–8.5 dpc (Figure 2B). To conﬁrm that the Suz12
protein was not expressed in the KO embryos, we prepared
protein lysates from whole 8.5 dpc embryos, and analyzed
the Suz12 protein levels using an antibody generated against
a 179 aa C-terminal portion of Suz12. Western blot analysis
(WB) demonstrated that Suz12 is expressed in normal 8.5 dpc
embryos while, consistent with their genotype, none of the
mutant embryos had detectable levels of WT Suz12
(Figure 2C). Interestingly, the Ezh2 levels were strongly
reduced (Figure 2C), suggesting that Suz12 could be required
for the stability of the Ezh2 protein. In contrast, Eed levels
were only decreased to a minor extent in mutant embryos.
Our results suggest that Suz12 loss results in improper
development around 7.5 dpc and that this phenotype could
depend directly on the loss of the PRC2/3 complex activity.
To better understand these observations, we analyzed em-
bryos from Suz12þ / intercrosses at 7.5 dpc. Hematoxylin
and eosin (H&E) staining at 7.5 dpc (Figure 3A, top
panels) showed that KO embryos were signiﬁcantly reduced
in size and had several developmental defects. Immuno-
histochemical (IHC) staining demonstrated that Suz12 was
strongly expressed in WT but completely lost in KO embryos
(Figure 3A, middle panels). As a conﬁrmation for the speci-
ﬁcity of the Suz12 antibody, we showed that Suz12 expres-
sion was detected in the maternal tissues proximal to the
uterus cavity in both the WTand mutant embryos (Figure 3A,
bottom panels). Mutant embryos present severe defects in the
development of most of the common structures of a 7.5 dpc
embryo. The amniotic, exocoelomic and ectoplacental
cavities appear not to form correctly and neither amnion
nor chorion was distinguishable. The distinction between the
three embryonic sheets was also difﬁcult to appreciate. In
addition, an aberrant presence of vacuolated cells was found
in the region of the ectoplacental cavity. Very similar results
were reported for the Ezh2- and Eed-deﬁcient mice (Faust
et al, 1995, 1998; O’Carroll et al, 2001). Furthermore,
Faust et al have carried out an extensive and detailed
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Figure 2 Suz12 is required for early embryonic development. (A)
Picture and PCR analysis of 10.5 dpc embryos from Suz12þ /
intercrosses showing nearly complete reabsorption of Suz12 KO
embryos. (B) Picture and PCR analysis of 8.5 dpc embryos from
Suz12þ / intercrosses showing the developmental defects of
Suz12 KO embryos. (C) Picture and WB analysis of 8.5 dpc embryos
from Suz12þ / intercrosses showing the complete absence of the
Suz12 WT protein and the strong reduction of the Ezh2 protein
levels in the KO embryos. b-Tubulin was used as loading control.
(D) Picture and WB analysis of 8.5 dpc embryos from Suz12þ /
intercrosses showing loss of H3K27 di/trimethylation. Each lane
corresponds to a pool of four WT and four SUZ12 KO embryos. A
representative picture of the pooled embryos is presented on top of
each lane. Histone H3 and b-tubulin were used as loading control.
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characterization of the Eed mutant mice, using different
markers of gastrulation, which conﬁrmed the morphological
defects observed in these mutant embryos. Taken together
with the previous observations, we conclude that like Ezh2
and Eed, Suz12 KO embryos present strong defects in gas-
trulation.
To monitor the ability of the mutant embryos to develop
further, we analyzed embryos at 8.5 dpc. Embryo sections
were stained to visualize morphological changes (H&E) and
for the expression of Suz12 (Figure 3B). At 8.5 dpc, the
difference in size between normal and mutant embryos was
greater than at 7.5 dpc. Mutant embryos appear unable to
develop, and KO embryos have a similar morphology to the
7.5 Suz12/ embryos. The amnion does not extend and the
amniotic cavity is not folding around the embryo. In addition,
the neural ectoderm does not develop resulting in the com-
plete absence of organogenesis.
In summary, our results demonstrate that Suz12 KO em-
bryos are able to implant in the uterus, but that the post-
implantation development is strongly compromised most
likely due to gastrulating defects that induce a developmental
block around 7.5 dpc.
Di- and trimethylation of H3K27 is lost in Suz12
KO embryos
Considering the high similarity of Suz12, Eed and Ezh2 KO
embryos and the strong reduction in the levels of Ezh2
(Figure 2C) in Suz12 KO embryos, it is reasonable to spec-
ulate that since Suz12 is a subunit of the PRC2 complex,
Suz12 could have an essential role in the PRC2 complex
activity. To address this, we tested whether Suz12 loss
changed the methylation pattern of histone H3 K27 during
embryogenesis. As demonstrated in Figures 3C and D, ma-
ternal and WT embryonic cells stained strongly for H3K27
methylation, using an antibody speciﬁc for the di- and
trimethylated forms. In contrast, loss of Suz12 led to a
striking absence of both di- and trimethylated H3K27 in the
embryo, whereas the surrounding maternal tissue was not
affected. WB analysis performed on WT and SUZ12 mutant
8.5 dpc embryos conﬁrmed the reduction in di- and trimethy-
lation of H3K27 (Figure 2D), and interestingly showed that
monomethylation of H3K27 was not affected. These results
demonstrate that Suz12 is essential for di- and trimethylation
of H3K27 during embryogenesis.
Proliferation is strongly impaired in Suz12 KO embryos
To understand whether Suz12 is required for embryonic
proliferation, we analyzed the replicative and mitotic indices
of WT and KO embryos. As shown in Figures 4A–D, loss of
Suz12 leads to a signiﬁcant reduction in cells positive for both
BrdU and the serine 10 phosphorylated form of histone H3
(H3-P(S10), a marker of mitosis) at 7.5 dpc. Similar results
were also obtained at 8.5 dpc (see Supplementary informa-
tion). Thus, Suz12 KO embryos fail to proliferate providing a
likely explanation for the difference in sizes between WTand
KO embryos.
Interestingly, we observed that the reduction of BrdU-
positive cells in KO embryos was not as strong as the
reduction in H3-P(S10)-positive cells. This may suggest that
some BrdU-positive cells failed to enter mitosis and we
analyzed whether a checkpoint was induced in Suz12 KO
embryos. However, both the analysis of p53 levels and the
phosphorylation of H2AX (as a measure for an S-phase
checkpoint) showed no difference between WT and KO
embryos (Supplementary information). In contrast, we ob-
served that a large number of cells in the Suz12 KO embryos
underwent cell death as revealed by TUNEL staining
(Figure 4E and Supplementary information). These results
suggest that the developmental defects induced by loss of
PRC2/3 HMT activities lead to a strong decrease in prolifera-
tion and survival.
SUZ12 is required for proliferation in differentiated
tissue culture cells
Two subunits of the PRC2/3 complexes, EZH2 and EED, are
known to be required for the proliferation of both primary
and tumor cell lines (Varambally et al, 2002; Bracken et al,
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Figure 3 Developmental defects and lack of H3K27 methylation in
Suz12 KO embryos. (A) (Top panels) H&E staining of 7.5 dpc in
utero embryo sections from Suz12þ / intercrosses showing nor-
mal morphology of WT and developmental defects of Suz12 KO
embryos. (Middle panels) IHC staining showing the presence or
absence of the WT Suz12 protein in consecutive sections of the
embryos shown in the top panels. (Lower panels) IHC staining for
Suz12 in the uterus of each section is presented as a control for
proper staining of the analyzed sections. ec: ectoplacental cone;
epc: ectoplacental cavity; c: chorion; a: amnion; ne: neural ecto-
derm; ys: yolk sac. (B) H&E (left and middle panels) and Suz12 IHC
staining (right panels) in the embryos and in the uterus of 8.5 dpc
in utero embryo sections from Suz12þ / intercrosses. Different
magniﬁcations of the same embryos are presented to better evaluate
the differences in size and morphology between WT and KO
embryos. ac: amniotic cavity; s: somites; nt: neural tube; nc:
notochord. (C) Different magniﬁcations of IHC staining of H3K27
di/trimethylation in WT (left panels) and Suz12 KO (middle and
right panels) 7.5 dpc embryos. (D) As in panel (C), but for 8.5 dpc
embryos. WT (left panels) and Suz12 KO (right panels) embryos.
Suz12 IHC staining of maternal cells in (C, D) was used as antibody
staining control.
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2003). We observed that in vivo, KO embryos for Suz12
present proliferative defects suggesting that SUZ12 is also
required for proliferation of human differentiated cells.
To characterize the role of the human SUZ12 protein in
cellular proliferation, we tested seven different siRNA oligo-
nucleotides that speciﬁcally target the SUZ12 transcript and
identiﬁed one that efﬁciently reduced SUZ12 expression to
nearly undetectable levels (data not shown). This sequence
works efﬁciently in both transient transfection as double-
stranded RNA and in the retroviral vector pRetroSuper (pRS)
(Brummelkamp et al, 2002). To determine the effect of SUZ12
loss in human tumor cells, we infected the osteosarcoma
tumor cell line U2OS with both pRS and pRS-SUZ12 vectors.
The infected cells were plated at low density and stained with
crystal violet 2 weeks after plating. The SUZ12 levels were
efﬁciently reduced as shown byWB (Figure 5A). Reduction of
SUZ12 levels resulted in a signiﬁcant decrease in the colony
forming ability of U2OS cells, demonstrating that SUZ12 is
required for proliferation (Figure 5A).
To test whether SUZ12 is also required for proliferation of
human diploid cells, we infected TERT immortalized human
diploid lung ﬁbroblasts (TIG3-T) with both pRS-empty and
pRS-SUZ12. Colony formation assays (Figure 5B) and growth
curves (Figure 5C) showed that the proliferation of the SUZ12
interfered cells was strongly compromised. Consistent with
this, FACS analysis demonstrated that BrdU incorporation
of SUZ12 TIG3-T interfered cells was signiﬁcantly reduced
compared to control cells, leading to an increase in the
number of cells in G1 (Figure 5D). WB analysis conﬁrmed
that SUZ12 levels were efﬁciently reduced throughout the
experiment (Figure 5E, top panel) and, consistent with the
results obtained in mouse embryos, loss of SUZ12 led to a
strong reduction of EZH2 levels in human cells (Figure 5E,
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Figure 4 SUZ12 KO embryos are compromised in proliferation. (A)
Different magniﬁcations of IHC staining of BrdU in WT (top panels)
and KO (bottom panels) 7.5 dpc embryos. The mice were injected
with BrdU (150mg/kg) for 60min before they were killed. (B)
Average of the percentage of BrdU-positive cells in both WT and
KO embryos. The standard deviation (s.d.) of the mean is indicated.
A total of 1086 cells inWTembryos and 936 cells in KO embryos were
counted. (C) Different magniﬁcations of IHC staining of phosphor-
ylation of Ser10 of histone H3 in WT (top panels) and KO (bottom
panels) 7.5dpc embryos. (D) Average of the percentage of H3 Ser10
phosphorylated cells in both WTand KO embryos. s.d. is indicated. A
total of 501 cells in WT embryos and 309 cells in KO embryos were
counted. (E) Different magniﬁcations of TUNEL staining in WT (top
panels) and KO (bottom panels) 7.5dpc embryos.
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Figure 5 SUZ12 is required for proliferation of both normal and
tumor cells. (A) Colony formation of U2OS cells stably interfered
with empty (CTRL) and SUZ12 shRNA (SUZ12) retroviral vectors
showing the proliferative impairment of SUZ12 interfered U2OS
cells. In the bottom panels, WB analyses of SUZ12 levels of the
same cells are presented. b-Tubulin was used as loading control.
(B–D) Colony, growth curves and BrdU FACS analysis of primary
human TIG3-Tcells stably interfered with empty (CTRL) and SUZ12
shRNA (SUZ12) retroviral vectors, showing the requirement of
SUZ12 for proliferation of diploid human cells. (E) WB analysis of
TIG3-Tcells at each day of the experiment presented in (C), showing
the efﬁciency of the SUZ12 interference and the reduction of the
EZH2 protein levels. b-Tubulin served as loading control. (F) Serum
induction of serum-starved human diploid ﬁbroblasts. WB analyses
show the accumulation of both SUZ12 and cyclin A2 at the G1–S
transition. b-Tubulin was used as loading control. (G) SUZ12 is
required for S-phase entry. BrdU incorporation was measured with
(24 h) and without (0 h) serum induction of serum-starved TIG3-T
cells stably interfered with empty (CTRL) and SUZ12 shRNA
(SUZ12) retroviral vectors.
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bottom panel) further suggesting a role of Suz12 in the
activity and/or stability of the PRC2/3 complex.
We and others have identiﬁed SUZ12 as a target of the E2F
transcription factors (Muller et al, 2001; Weinmann et al,
2001; Bracken et al, 2003). In agreement with this, the SUZ12
protein levels are strongly reduced in quiescent cells and
subsequently accumulate at the G1–S transition with kinetics
similar to cyclin A2 (Figure 5F). To understand whether
SUZ12 is required for cells to re-enter the cell cycle, we
serum-starved TIG3-T cells stably interfered with both
empty and pRS-SUZ12 vectors. Upon cell cycle re-entry, the
absence of SUZ12 strongly impaired the ability of the cells to
re-enter the cell cycle (Figure 5G). In summary, these results
demonstrate that SUZ12 is essential for the proliferation of
both tumor and diploid human cells, and for the expression
of EZH2.
SUZ12 is required for the integrity of the PRC2/3
complexes
Loss of SUZ12 expression both in vivo and in tissue culture
cells strongly reduced the levels of EZH2, suggesting that
SUZ12 may be required for the stability of the PRC2/3
complexes. To address this, we transiently interfered with
the expression of SUZ12 in HeLa cells by using siRNA oligos.
The interference efﬁciency was controlled by WB analysis
(Figure 6A). Protein lysates were prepared from control and
SUZ12 interfered cells and separated on a Superose 6 gel
ﬁltration column. The elution proﬁle of the different compo-
nents of the PRC2 complex was monitored by WB analysis.
The elution proﬁle in cells interfered with control siRNA
(Figure 6B) showed that SUZ12 is found in a 700 kDa com-
plex, and consistent with being part of the PRC2/3 com-
plexes, EZH2 and EED also coeluted in these fractions
(Figure 6B). Strikingly, when cells were transfected with
SUZ12 RNAi, the EZH2 and EED 700 kDa forms disappeared,
and the two proteins accumulated in smaller fractions
(Figure 6B). These results demonstrate that SUZ12 is required
for the integrity of the PRC2/3 complexes.
To determine whether disruption of the complexes affects
the enzymatic activities, we transfected HeLa cells with
control and EZH2- and SUZ12-speciﬁc siRNAs. Lysates were
immunoprecipitated with preimmune or anti-EZH2 serum
and the immunoprecipitation (IP) products were incubated
in an in vitro HMTassay. As shown in Figures 6C–E, the EZH2
antibody precipitated a strong HMT activity speciﬁc for
histone H3. This activity was EZH2 speciﬁc since it was
strongly reduced in cells transfected with siRNA to EZH2.
Signiﬁcantly, however, together with the demonstration that
SUZ12 is essential for the integrity of the PRC2/3 complexes,
EZH2 enzymatic activity was also strongly compromised
upon SUZ12 downregulation, demonstrating that SUZ12 is
required for EZH2 HMT activity.
To address the role of SUZ12 in the stability of the PRC2/3
complexes, we tested whether short-term SUZ12 downregu-
lation affected the transcription of EZH2 or stability of the
EZH2 protein. To address this, we analyzed by real-time
quantitative PCR the transcription of the three core compo-
nents of the PRC2/3 complex after transient downregulation
of SUZ12. We did not observe any signiﬁcant changes in the
expression of EZH2 and EED mRNAs, suggesting that short-
term downregulation of SUZ12 affects the stability of EZH2
rather than its gene transcription (Figure 6F). To test this
directly, we incubated HeLa cells transiently transfected with
SUZ12-speciﬁc siRNA with the proteosome inhibitor MG132
for 10 h before harvesting. As shown in Figure 6G, treatment
of HeLa cells with MG132, but not carrier, resulted in
stabilization of EZH2. These results demonstrate that
SUZ12 prevents the proteolytic degradation of EZH2 by
regulating the stability and the enzymatic activity of EZH2-
containing complexes.
To understand if the loss of HMT activity is due to EZH2
degradation or whether SUZ12 directly contributes to the
enzymatic activity of the complex, we reconstituted the
PRC2 complex in vitro using a baculovirus expression system.
As shown in Figure 7A, in the absence of Suz12, the recruit-
ment of the subunit RbAp48 is prevented but not the binding
between EZH2 and EED. The absence of SUZ12 and the loss
of RbAp48 recruitment result in the loss of EZH2 HMTactivity
on both histones H3 and H1 (Figure 7B). In contrast, the
absence of RbAp48 allows the formation of an EZH2–SUZ12–
Eed trimeric complex active on both histones H3 and H1
(Figure 7B). In order to obtain an equal amount of stoichio-
metric complexes, we further puriﬁed the different PRC2
complexes by gel ﬁltration (Figure 7C). Fractions containing
the different complexes were assayed for HMT activity
(Figure 7D, top panel). In the absence of RbAp48, the PRC2
complex is functional but is less efﬁcient than when RbAp48
is present, suggesting that RbAp48 enhances the EZH2 HMT
activity. These results demonstrate that SUZ12 is essential for
EZH2 HMT activity on both histones H3 and H1 and that
SUZ12 enhances this activity by mediating the recruitment of
the histone-binding subunit RbAp48 to the PRC2/3 com-
plexes.
Discussion
We have investigated the role of the PcG protein Suz12 in vivo
and in tissue culture and have demonstrated that Suz12 is an
essential regulator of the activity and stability of the PRC2/3
complexes in both mouse embryogenesis and in human
differentiated cells. We have shown that mice lacking func-
tional Suz12 are not viable and die around day 7.5 of
embryogenesis. Moreover, we have shown that Suz12 mutant
embryos are impaired in proliferation and contain an in-
creased number of apoptotic cells. Proliferative defects were
also observed in human tissue culture cells, demonstrating
that SUZ12 is required for proliferation and for S-phase entry
of serum-stimulated quiescent cells. We have shown that
SUZ12 has an essential role in stabilizing the PRC2/3 com-
plexes and maintaining their HMT activities. Disruption of
these complexes results in the speciﬁc loss of di- and
trimethylation of H3K27 in vivo and in the loss of EZH2
HMT activity in vitro. Moreover, we have demonstrated that
SUZ12 is required for the enzymatic activity of EZH2 on both
histones H3 and H1 and that SUZ12 enhances this activity.
Suz12 and mouse development
SUZ12, together with EZH2, EED and RbAp46/48, forms a
complex, which has been shown to contain intrinsic K9/K27
HMT activity (Cao et al, 2002; Czermin et al, 2002;
Kuzmichev et al, 2002; Muller et al, 2002). This complex
has also been shown recently to contain histone H1K26
methyl transferase activity (Kuzmichev et al, 2004). Ezh2
and Eed are both essential for mouse development and their
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loss results in embryonic lethality. The mutant embryos are
able to go beyond the preimplantation stage and to implant in
the uterus, but serious developmental defects arise between
6.5 and 8.5 dpc (Faust et al, 1995; O’Carroll et al, 2001).
Gastrulation of the mutant embryos initiates, but fails to
correctly develop. Proper embryonic tissues do not form
and aberrant outgrowth of mesoderm cells in extraembryonic
tissues is observed. In this study, we demonstrate that Suz12
mutant embryos have defects similar to those observed in
Ezh2 and Eed KO embryos. Suz12-deﬁcient embryos are able
to implant, but their development is blocked around day 7.5.
Embryonic and extraembryonic structures in Suz12 KOs do
not seem to develop and, like Ezh2 and Eed KOs, organogen-
esis does not initiate. The difference between WTand mutant
embryos is even more evident at 8.5 dpc, when mutant
embryos are developmentally blocked and remain morpho-
logically similar to 7.5 dpc embryos.
Based on the signiﬁcant phenotypic similarities between
the KO embryos of Suz12, Eed and Ezh2, we propose that
these three genes contribute to the same activities.
Interestingly, SUZ12 is part of all EZH2-containing complexes
puriﬁed so far, suggesting a tight relationship between SUZ12
and EZH2 activities. Moreover, in Drosophila, mutants for
the EZH2 and SUZ12 homologs E(z) and Su(z)12 display a
similar pattern of homeotic genes deregulation (Jones and
Gelbart, 1990; Simon et al, 1992; Birve et al, 2001), suggest-
ing that the transcriptional effects imposed by E(z) and
Su(z)12 act in parallel if not identical pathways. In strong
support of this notion, we have demonstrated that SUZ12 is
required for EZH2 activity and that SUZ12 enhances the PRC2
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complex activity by mediating the recruitment of the histone-
binding protein RbAp48 to the complex in vitro. Consistent
with these in vitro data, we have shown that SUZ12 is
required for EZH2 HMTactivity in human cells and moreover
that H3K27 di- and trimethylation is lost in mouse embryos
lacking the Suz12 protein. In the last decade, an overwhelm-
ing amount of data has demonstrated the crucial role of
histone tail modiﬁcations in the regulation of gene transcrip-
tion. The role of H3K27 methylation is not fully character-
ized, but it has been linked to transcriptional repression of
euchromatic regions (Peters et al, 2003). While in vitro data
link EZH2 activity to different histone modiﬁcations, in vivo
data suggest that the main HMT activity of EZH2 is toward
H3K27 (Erhardt et al, 2003). Due to its recent discovery, no
data have so far been published regarding H1K26 methylation
in vivo. In this work, we have demonstrated that, at least in
vitro, SUZ12 is required for EZH2 histone H1K26 methylation,
but it will be interesting to understand whether EZH2 com-
plexes are indeed responsible for this modiﬁcation in vivo.
Taking our and others’ data into consideration, K27 methy-
lation is, at present, the most likely enzymatic activity by
which the EZH2 complex imposes its control on transcrip-
tion. Furthermore, since K27 methylation is widely spread
throughout the chromatin during embryogenesis and the
absence of Suz12 induces a global loss of K27 methylation
in vivo, our results suggest that the PRC2/3 complexes are
directly involved in controlling the expression of a large
number of genes. This result does not exclude the possibility
that independently of EZH2, SUZ12 could regulate the activ-
ity of other H3K27 HMT enzymes during embryogenesis. To
understand this, it would be interesting to investigate if
H3K27 methylation is lost in the implanted 7.5 dpc Ezh2 KO
embryos, as reported in Ezh2/ blastocysts (Erhardt et al,
2003). Alternatively, the PRC2/3 complexes might be re-
quired for the activity of other H3K27 methyltransferases,
and the global loss of H3K27 methylation observed in the
Suz12-deﬁcient embryos could therefore reﬂect the lack of
activity of several H3K27 methyltransferases. Another possi-
bility is that the EZH2-containing complexes are involved in
the general control of chromatin folding and only indirectly
inﬂuence transcription. In support of this, E(z), the
Drosophila homolog of EZH2, is required for the proper
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condensation of Drosophila polytene chromosomes (Rastelli
et al, 1993). A functional link between EZH2-dependent
H1K26 methylation and chromosome condensation has
been recently proposed by Kuzmichev et al (2004). Future
work involving the identiﬁcation of target genes for the
EZH2-containing complexes, the identiﬁcation of other
H3K27 methyltransferases and more studies on the function
of H1K26 methylation will most certainly provide more in-
sights into these questions.
SUZ12 and cellular proliferation
The expression of Suz12 is linked to proliferation and the
protein levels are strongly reduced in noncycling compared to
cycling cells. We have demonstrated that Suz12 KO embryos,
in addition to strong developmental defects, are also severely
impaired in proliferation. Since development is strictly linked
to proliferation during embryogenesis, it is not possible to
determine whether the proliferative defects of the Suz12 KO
embryos are due to developmental failures or, conversely,
whether the developmental failures are due to lack of pro-
liferation. However, we have also demonstrated that SUZ12 is
essential for proliferation of human cells in tissue culture.
This is consistent with previous reports demonstrating that
EZH2 and EED are also required for proliferation of both
tumor and primary cells (Varambally et al, 2002; Bracken
et al, 2003). Supporting this notion is the fact that the three
PcG genes are transcriptionally regulated by the pRB/E2F
pathway, and that they are required for S-phase entry.
Although proliferation in tissue culture is not directly com-
parable with proliferation during embryogenesis, these re-
sults suggest that the EZH2-containing complexes are
involved in the regulation of genes essential for proliferation.
Interestingly, Suz12, Ezh2 and Eed KO mice die during devel-
opment before the transcription of the Hox genes (reviewed
in van Lohuizen, 1998), strongly suggesting that the EZH2-
containing complexes have targets other than the Hox genes
that are essential for proper development and/or prolifera-
tion. Future studies will be aimed at identifying novel PRC2/3
target genes.
Stability and functionality of the PRC2 complex
The data that we have presented on the role of SUZ12 in
regulating PRC2/3 function(s) highlight SUZ12 as an essential
regulator of these complexes. Monomeric EZH2 does not
possess enzymatic activity (Cao et al, 2002; Czermin et al,
2002; Kuzmichev et al, 2002; Muller et al, 2002), and in
agreement with this we have demonstrated that abrogation of
SUZ12 expression resulted in loss of EZH2 HMT activity in
vivo and in vitro. This is explained by the fact that SUZ12 is
required for the activity of the PRC2/3 complexes and for the
stability of the EZH2 protein. Since deregulation of EZH2 can
have a causal role in cancer, it is tempting to speculate that
stabilization of EZH2 by mutations in genes required for its
degradation could be involved in cancer as well.
In conclusion, we have shown that SUZ12 is essential for
the integrity of the PRC2/3 complexes, the stability of EZH2
and hence the HMT activity of these complexes (Figure 7E).
We propose that loss of SUZ12 induces changes in the
chromatin structure of PRC2/3 target genes. These changes
will result in the misregulation of the expression of PRC2/3
target genes, subsequently leading to severe developmental
and proliferative defects.
Materials and methods
Generation and genotyping of Suz12 KO mice
Suz12 genetrapped ES cells (XG122) (http://www.baygenomic-
s.ucsf.edu) were used to generate chimeric mice. Suz12 hetero-
zygous mice were interbred to generate Suz12-deﬁcient embryos.
ES cells and mice were genotyped either by Southern blotting or
PCR analysis. Southern blots were probed with a 432 bp fragment
generated by PCR from normal C57BL/6 genomic DNA using the
primers Fwd 50-CTCCATTCCCAAGCCATTTATTC-30 and Rev 50-
AACAGCAACGAGTAGGACTTCACC-30 and conﬁrmed by sequen-
cing. Genomic DNA was digested with ACC I (Roche, catalog no.
728-420), separated on a 1.2% agarose gel and transferred to a
Hybond Nþ membrane (Amersham). The membrane was prehy-
bridized at 651C for 60min with hybridization buffer (PerfectHybTM
Sigma). The probe was labeled with [a-32P]dCTP using Rediprime-II
DNA labeling system (Amersham), puriﬁed with Sephadex G-50
column (Roche) and added to the hybridization buffer for 3 h. The
membrane was washed twice with 2 SSC/0.2% SDS at room
temperature (RT) for 15min and for two times with 0.2 SSC/0.2%
SDS at 651C for 20min.
PCR genotyping was performed using the following primers:
WT allele, Fwd 50-GAAGTCCTACTCGTTGCTGTTTAG-30 and Rev
50-CATTTGTGCAACAAATGTCTTTTC-30 (1709 bp PCR product); KO
allele (LacZ PCR): Fwd 50-TGGTCGCTGGGGAATGAATC-30 and Rev
50-AACGGGGATACTGACGAAACG-30 (318 bp PCR product).
FISH analysis
FISH analyses on the genetrapped ES cells were performed as
described (Bracken et al, 2003). The probe speciﬁc for the
BayGenomics insertion cassette vector pGT1lxf (http://www.bay-
genomics.ucsf.edu) was generated by PCR using genomic DNA of
Suz12 genetrapped ES cells with the following primers: Fwd 50-
GCTGGCGTAATAGCGAAGAGG-30 and Rev 50-TTTTATGTTTCAGGT
TCAGGGGG-30. The PCR product was cloned into pCRs2.1 TOPOs
vector (Invitrogen) and conﬁrmed by sequencing. The plasmid was
subsequently used to perform FISH analysis.
Embryo harvesting and histological analysis
See Supplementary materials.
Cloning and RNAi
The SUZ12-speciﬁc sequence (AAGCTGTTACCAAGCTCCGTG) was
used to synthesize double-stranded siRNA oligos (MWG) or cloned
into pRetroSuper (Brummelkamp et al, 2002). EZH2 and Eed open
reading frames (ORFs) described by Bracken et al (2003) were
cloned respectively into pFastBac1 and pFastBacHTb (Invitrogen).
SUZ12 (NM_015355) and RbAp48 ORFs (NM_005610) were isolated
from human primary TIG3 ﬁbroblasts by PCR, cloned into
pFastBac1 and the DNA sequences were veriﬁed by sequencing.
Tissue culture
U2OS, HeLa and TIG3-T (stably expressing TERT) cells were
cultured in DMEM supplemented with 10% (v/v) FCS. Low-density
assays of U2OS and TIG-3 cells were performed in 10 cm tissue
culture dishes and stained with crystal violet.
Growth curves: TIG 3-T cells were infected with the indicated
retroviral constructs, selected for 3 days in 500mg/ml puromycin
and plated in six-well dishes. Viable cells were counted by Trypan
blue staining and lysed for WB analysis.
Transient RNAi: A total of 7105 HeLa cells were plated in 10 cm
dishes, transfected after 24 h with Oligofectamines (Invitrogen)
following the manufacturer’s protocol and collected at the indicated
time.
FACS analysis: TIG3-Twas grown to 60–70% conﬂuency, treated
with 0.3mM BrdU for 60min (Sigma, catalog no. 59-14-3) and
harvested. Cells (3106) were treated and analyzed by FACS as
described (Bracken et al, 2003).
Antibodies
The rabbit anti-EZH2 sera were generated against the N-terminal
286 aa of EZH2, which was fused to the maltose-binding protein
(MBP). Mouse monoclonal antibodies were produced as described
(Bracken et al, 2003). AC22 (anti-EZH2) was generated using aa
353–451 of EZH2 fused to MBP as an immunogen. AE25 (anti-
EZH2) was generated using aa 1–286 of EZH2 fused to MBP as an
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immunogen. AI25-13 (anti-p53) was raised in p53/ C57BL6
using mouse WT p53 as an immunogen. AA19 (anti-EED) and
mouse monoclonal anti-di/trimethyl histone H3K27 have been
described previously (Bracken et al, 2003; Okamoto et al, 2004).
Other antibodies are commercially available: rabbit anti-Suz12
(Upstate), rabbit anti-histone H3 phospho-Ser10 (Upstate), mouse
anti-b-Gal (Santa Cruz), rabbit anti-b-tubulin (Santa Cruz), mouse
anti-BrdU (Beckson & Dickinson), mouse anti-H2AX (Upstate) and
rabbit anti-monomethyl histone H3K27 (Upstate).
Biochemical and enzymatic analyses
Column separation: HeLa cells transfected with siRNA oligonucleo-
tides were lysed in column buffer (25mM HEPES pH 7.6, 1mM
EDTA, 10% glycerol, 300mM NaCl) 48 h after transfection and
separated on a Superose 6 PC 3.2/30 gel ﬁltration column
(Amersham). Fractions were analyzed by WB.
HMTassay: HeLa cells transfected with siRNA oligos were lysed
in IP buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA,
1mM EGTA, 0.1% Tween 20) 48 h after transfection. A 5mg portion
of the extracts was immunoprecipitated overnight with the
indicated antibodies.
Sf9 cells (Invitrogen, catalog no. 25-0127) were infected with the
indicated virus produced using Bac-to-Bacs HT Baculovirus
Expression System following the manufacturer’s procedure (Invi-
trogen). Cells were lysed in BPL2B buffer (20mM Tris–HCl pH 8,
500mM NaCl, 20% glycerol, 4mM MgCl2, 3mM 2-mercaptoetha-
nol, 0.05% NP-40). Proteins were puriﬁed using Ni-NTA agarose
(Invitrogen) and eluted in ERB (50mM Tris–HCl pH 8.5, 150mM
NaCl, 5mM MgCl2, 5mM DTT, 300mM imidazole).
Puriﬁed products, when indicated, were loaded on a Superdex
200 PC 3.2/30 gel ﬁltration column (Amersham) and eluted in ERB
in the absence of imidazole. Puriﬁed products and indicated
fractions were incubated in 5HMT buffer for 60min at 301C
(250mM Tris–HCl pH 8.5, 25mM MgCl2, 20mM DTT, 15 mCi/ml
S-adenosyl-L-[methyl-3H]methionine (Amersham, catalog no.
TRK581), 0.1mg/ml of histone mixture (Roche, catalog no.
0223565)). When indicated, the following substrates were used:
histone recombinant octamers produced as described by Kuzmi-
chev et al (2004); HeLa S3 oligonucleosomes produced as described
by Fang et al (2004), oligonucleosomes with histone H1 as
described by Kuzmichev et al (2004). The reaction products were
denatured and separated on SDS–polyacrylamide gels. Proteins
were transferred to PVDF membranes and histones were visualized
by Coomassie staining. HMT activity was measured by ﬁlm
exposure of the membrane.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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